Bristol-Myers Squibb Company
BMY
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Bristol Myers Squibb (BMY) has a massive, highly documented lobbying and litigation footprint specifically designed to block democratically enacted drug pricing reforms.
Senate HELP Committee investigation (June 2024): Bristol-Myers Squibb used REMS (Risk Evaluation and Mitigation Strategy) safety program as anticompetitive tool to block generic entry for Revlimid (lenalidomide), enabling a 30x price increase over patent life. BMS charged US patients $763/pill vs $5 in India. Senate report documents systematic abuse of FDA safety programs to extend monopoly pricing.
Research Sources
3 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.